Our top priority is the health and safety of our community. Visit our COVID-19 information page to see how we’re responding to the public health emergency.

Patient support in one location.

animated lifters

PATIENT SERVICES FOR DOJOLVI

Ultragenyx is committed to patients with rare diseases, which is why we created UltraCare Patient Services for DOJOLVI—your patients’ guide throughout their DOJOLVI treatment journeys.

Our UltraCare Case Managers have varied backgrounds, including social workers, healthcare professionals, and patient advocates, and are ready to help patients gain and maintain access to DOJOLVI.

UltraCare Case Managers help patients and their caregivers with:

  • Reimbursement Navigation
  • Educational Support
  • Adherence Support
  • Financial Support
  • Pharmacy Services
  • Bilingual Support

HOW TO ENROLL YOUR PATIENTS IN ULTRACARE

Step 1: Complete the
Enrollment Form with your
patient.

Step 2: Fax the completed*
Enrollment Form to 1-833-592-2273 (CARE).

Contact our UltraCare Case Managers for additional support at 1-833-388-5872 (U-LTRA).

Visit UltraCare

*Please note that a completed form is required for patient enrollment.

Download DOJOLVI materials

DOJOLVI
Enrollment Form


Complete the Enrollment Form to prescribe DOJOLVI

DOJOLVI® (triheptanoin) Start Form

Download

DOJOLVI Patient Brochure
and Dosing Guide


Information for your patients about LC-FAOD, DOJOLVI, and support available to them

DOJOLVI® (triheptanoin) Patient Brochure

Download

Daily
Dosing Tracker
 


A tool your patients can use to keep track of DOJOLVI doses

DOJOLVI® (triheptanoin) Daily Dosing Tracker

Download

Dojolvi Product Monograph


An easy-to-read, large-format version of the full DOJOLVI Product Monograph

DOJOLVI Prescribing Information (PI) Booklet

Download

Materials Compatibility
Reference


A reference overview of materials that are compatible or incompatible to use with DOJOLVI

A reference overview of materials that are compatible or incompatible to use with DOJOLVI

Download

Instructional Dosing Videos

Precautions
Press-in Bottle Adapter
Syringe Dosing
Syringe Cleaning
Dosing Cup
Dosing Cup Cleaning

Instructional Mixing Videos

Mixing DOJOLVI into fat-free milk
Mixing DOJOLVI into fat-free yogurt
Mixing DOJOLVI into whole-grain hot cereal
Mixing DOJOLVI into a fat-free, low-carbohydrate smoothie

Stay Informed

Sign up to receive more information and updates about DOJOLVI.

FOR CANADIAN HEALTHCARE PROFESSIONALS

INDICATION

DOJOLVI® (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Clinical Use

The safety and efficacy of DOJOLVI in pediatric patients have been established. Clinical studies of DOJOLVI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Contraindications

Triheptanoin is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Most Serious Warnings and Precautions

  • Feeding tube dysfunction: Performance and functionality can degrade over time depending on usage and environmental conditions. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.
  • Intestinal malabsorption in patients with pancreatic insufficiency: Low or absent pancreatic enzymes may reduce absorption of heptanoate leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

For More Information

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions and dosing instructions, including dosage adjustment, which have not been discussed in this piece. 

The Product Monograph is also available by calling 1-833-388-5872.

INDICATION

DOJOLVI® (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Clinical Use

The safety and efficacy of DOJOLVI in pediatric patients have been established. Clinical studies of DOJOLVI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Contraindications

Triheptanoin is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Most Serious Warnings and Precautions

  • Feeding tube dysfunction: Performance and functionality can degrade over time depending on usage and environmental conditions. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.
  • Intestinal malabsorption in patients with pancreatic insufficiency: Low or absent pancreatic enzymes may reduce absorption of heptanoate leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

For More Information

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions and dosing instructions, including dosage adjustment, which have not been discussed in this piece. 

The Product Monograph is also available by calling 1-833-388-5872.